ABSTRACT
Botulinum toxin A is widely used in the aesthetic treatment of dynamic facial lines, especially the glabellar lines (“frown” lines between the brows) and lateral canthal lines (crow's feet). Several commercial forms of botulinum toxin A are available but, currently, they all need to be injected into the skin or underlying muscle. As injections can be associated with needle anxiety and the potential for bruising, discomfort, and infection, a topical formulation has been developed. This gel formulation contains daxibotulinumtoxinA bound non-covalently to a peptide carrier that transports the toxin across the skin. Preclinical and clinical studies have evaluated the potential of this novel method of botulinum toxin delivery.
